接種對象
一、暴露前預防(PrEP)：
(一) 正痘病毒屬之實驗室操作人員。
(二) 與確診M痘個案曾有任何形式性接觸之高風險接觸者，但未曾接種過暴露後預防(PEP)疫苗。
(三) 近 6 個月內曾有高風險性行為者，例如：多重性伴侶、性交易服務者、於營業場所發生性行為者、性病患者等。
(四) 照顧M痘確診個案之醫療照護與清消人員，以及協助疑似M痘個案檢體採檢或執行M痘疫苗接種作業人員。
二、暴露後預防(PEP)：「M痘疫情調查及接觸者追蹤指引之接觸者匡列處置原則」所列高暴露風險接觸者。
三、其他特殊狀況報經疾管署同意者。

Vaccine; Vaccine, Live, Non-Replicating (Viral)

Onset of action: peak antibody response for Jynneos is typically achieved 2 weeks after completion of the 2-dose series.

Serious hypersensitivity to any component of the formulation；Acute febrile illness if used for nonemergency (preexposure) prophylaxis.

>10%: change in appetite (15% to 20%), nausea (10% to 23%), erythema at injection site (SUBQ: 61% to 81%; intradermal: 100%), induration at injection site (SUBQ: 45% to 70%; intradermal: 100%), injection-site pruritus (SUBQ: 32% to 49%; intradermal: 89%), pain at injection site (SUBQ: 80% to 91%; intradermal: 65%), swelling at injection site (SUBQ: 52% to 67%), chills (≤15%), fatigue (30% to 51%), headache (28% to 43%), arthralgia (9% to 18%), myalgia (22% to 43%).

Primary immunization:
Intradermal: 0.1 mL per dose given as 2 doses separated by 4 weeks.
SUBQ: 0.5 mL per dose given as 2 doses separated by 4 weeks.

For patients <18 years of age, only SUBQ administration is authorized.